Influence of transporter genetic polymorphisms on valproic acid blood concentration and clinical efficacy of epilepsy patients
10.13699/j.cnki.1001-6821.2016.03.007
- VernacularTitle:转运体基因多态性对癫痫患者丙戊酸血药浓度及临床疗效的影响
- Author:
Juan CHEN
1
;
Xue-Ding WANG
;
Lie-Min ZHOU
;
Hong-Liang LI
;
Ya-Fang ZHOU
;
Jia-Ming QIN
;
Qi-Lin DAI
;
Min HUANG
Author Information
1. 中山大学 药学院 临床药理研究所
- Keywords:
valproic acid;
transporter;
polymorphism;
blood concentra-tion;
clinical efficacy
- From:
The Chinese Journal of Clinical Pharmacology
2016;(3):215-217
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of ABCC2, MCT1, MCT2, OATP2B1 on valproic acid ( VPA) blood concentration and effi-cacy in epilepsy patients.Methods One hundred sixty epilepsy patients receiving VPA as monotherapy were included.Steady-state blood con-centration of VPA was measured by a high -performance liquid chroma-tography method.ABCC2 rs2273697 , rs3740066 , MCT1 rs60844753 , rs7169, MCT2 rs10784000 , rs10877333 , rs1693614 , OATP2B1 rs2306168 genotypes were detected by Sequenom Mass ARRAY ? sys-tem.The association between different genotypes and VPA concentration was analyzed by Kruskal -Wallis test.Efficacy comparison among geno-types were performed by Chi -square test.Results The concentration of valproic acid in ABCC2 rs2273697 AA genotype was considerably higher than the GA and GG genotypes ( P <0.05 ).There was no significant effect of other SNPs on VPA dose -adjusted concentration and clinical efficacy.Conclusion ABCC2 rs2273697 polymorphism is associated with valproic acid blood concentrations , and further studies are needed to verify the effect of this SNP on VPA blood concentration and clinical efficacy.
